Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities.
Andrés Méndez-Lucas,Xiaolei Li,Junjie Hu,Junjie Hu,Li Che,Xinhua Song,Jiaoyuan Jia,Jiaoyuan Jia,Jingxiao Wang,Chencheng Xie,Chencheng Xie,Paul C. Driscoll,Darjus F. Tschaharganeh,Darjus F. Tschaharganeh,Diego F. Calvisi,Mariia Yuneva,Xin Chen,Xin Chen +17 more
TLDR
It is suggested that increased expression of PKM2 is not required to support c-MYC-induced tumorigenesis in the liver and that various PKM1/PKM2 ratios and pyruvate kinase activities can sustain glucose catabolism required for this process.Abstract:
Different pyruvate kinase isoforms are expressed in a tissue-specific manner, with pyruvate kinase M2 (PKM2) suggested to be the predominant isoform in proliferating cells and cancer cells. Because of differential regulation of enzymatic activities, PKM2, but not PKM1, has been thought to favor cell proliferation. However, the role of PKM2 in tumorigenesis has been recently challenged. Here we report that increased glucose catabolism through glycolysis and increased pyruvate kinase activity in c-MYC-driven liver tumors are associated with increased expression of both PKM1 and PKM2 isoforms and decreased expression of the liver-specific isoform of pyruvate kinase, PKL. Depletion of PKM2 at the time of c-MYC overexpression in murine livers did not affect c-MYC-induced tumorigenesis and resulted in liver tumor formation with decreased pyruvate kinase activity and decreased catabolism of glucose into alanine and the Krebs cycle. An increased PKM1/PKM2 ratio by ectopic PKM1 expression further decreased glucose flux into serine biosynthesis and increased flux into lactate and the Krebs cycle, resulting in reduced total levels of serine. However, these changes also did not affect c-MYC-induced liver tumor development. These results suggest that increased expression of PKM2 is not required to support c-MYC-induced tumorigenesis in the liver and that various PKM1/PKM2 ratios and pyruvate kinase activities can sustain glucose catabolism required for this process. Cancer Res; 77(16); 4355-64. ©2017 AACR.read more
Citations
More filters
Journal ArticleDOI
Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma.
TL;DR: Targeting key factors in the glycolytic pathway such as the inhibition of HK2, PFK or PKM2, represent potential new therapeutic approaches for the treatment of HCC.
Journal ArticleDOI
Metabolic rearrangements in primary liver cancers: cause and consequences
Letizia Satriano,Monika Lewinska,Pedro Rodrigues,Jesus M. Banales,Jesus M. Banales,Jesper B. Andersen +5 more
TL;DR: The role of metabolic liver disruptions and the implications of these processes, emphasizing their clinical relevance and value in early diagnosis and prognosis and as putative therapeutic targets, are discussed.
Journal ArticleDOI
Emerging roles of aerobic glycolysis in breast cancer.
TL;DR: The present review attempts to address the implication of key enzymes of the aerobic glycolytic pathway including hexokin enzyme (HK), phosphofructokinase (PFK) and pyruvate kinase (PK), glucose transporters (GLUTs), together with related signaling pathways including protein kinase B(PI3K/AKT).
Journal ArticleDOI
Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis
Jiao Feng,Weiqi Dai,Yuqing Mao,Liwei Wu,Jingjing Li,Kan Chen,Qiang Yu,Rui Kong,Sainan Li,Jie Zhang,Jie Zhang,Jie Ji,Jianye Wu,Wenhui Mo,Xuanfu Xu,Chuanyong Guo +15 more
TL;DR: Simvastatin can inhibit the HIF-1α/PPAR-γ/PKM2 axis, by suppressing PKM2-mediated glycolysis, resulting in decreased proliferation and increased apoptosis in HCC cells, and re-sensitizing H CC cells to Sora.
Journal ArticleDOI
Identifying strategies to target the metabolic flexibility of tumours.
Andrés Méndez-Lucas,Wei Lin,Paul C. Driscoll,Nathalie Legrave,Laura Novellasdemunt,Chencheng Xie,Mark Charles,Zena Wilson,Neil P. Jones,Stephen Rayport,Manuel Rodriguez-Justo,Vivian S. W. Li,James I. MacRae,Nissim Hay,Xin Chen,Mariia Yuneva +15 more
TL;DR: The power of synergistic targeting of multiple metabolic pathways to stymie liver tumourigenesis is demonstrated and it is demonstrated that either pharmacological or dietary targeting of metabolic compensatory mechanisms can improve therapeutic outcomes.
References
More filters
Journal ArticleDOI
Hallmarks of cancer: the next generation.
TL;DR: Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.
Journal ArticleDOI
Tissue-based map of the human proteome
Mathias Uhlén,Mathias Uhlén,Linn Fagerberg,Björn M. Hallström,Cecilia Lindskog,Per Oksvold,Adil Mardinoglu,Åsa Sivertsson,Caroline Kampf,Evelina Sjöstedt,Evelina Sjöstedt,Anna Asplund,IngMarie Olsson,Karolina Edlund,Emma Lundberg,Sanjay Navani,Cristina Al-Khalili Szigyarto,Jacob Odeberg,Dijana Djureinovic,Jenny Ottosson Takanen,Sophia Hober,Tove Alm,Per-Henrik Edqvist,Holger Berling,Hanna Tegel,Jan Mulder,Johan Rockberg,Peter Nilsson,Jochen M. Schwenk,Marica Hamsten,Kalle von Feilitzen,Mattias Forsberg,Lukas Persson,Fredric Johansson,Martin Zwahlen,Gunnar von Heijne,Jens Nielsen,Jens Nielsen,Fredrik Pontén +38 more
TL;DR: In this paper, a map of the human tissue proteome based on an integrated omics approach that involves quantitative transcriptomics at the tissue and organ level, combined with tissue microarray-based immunohistochemistry, to achieve spatial localization of proteins down to the single-cell level.
Journal ArticleDOI
The Emerging Hallmarks of Cancer Metabolism
TL;DR: This Perspective has organized known cancer-associated metabolic changes into six hallmarks: deregulated uptake of glucose and amino acids, use of opportunistic modes of nutrient acquisition, useof glycolysis/TCA cycle intermediates for biosynthesis and NADPH production, increased demand for nitrogen, alterations in metabolite-driven gene regulation, and metabolic interactions with the microenvironment.
Journal ArticleDOI
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Weibo Luo,Hongxia Hu,Ryan Chang,Jun Zhong,Matthew K. Knabel,Robert N. O'Meally,Robert N. Cole,Akhilesh Pandey,Gregg L. Semenza +8 more
TL;DR: In this article, the pyruvate kinase isoforms PKM1 and PKM2 are alternatively spliced products of the PKM 2 gene, and they are activated by hypoxia-inducible factor 1 (HIF-1).
Journal ArticleDOI
HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer
TL;DR: A pathway that regulates an alternative splicing event required for tumour cell proliferation is defined, establishing a relevance to cancer, and it is demonstrated that human gliomas overexpress c-Myc, PTB, hnRNPA1 and hn RNPA2 in a manner that correlates with PKM2 expression.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more